New drug combo aims to boost chemoradiation for head and neck cancer
NCT ID NCT05172245
First seen Nov 01, 2025
Summary
This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combination to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Cabarrus/LCI-Concord
ACTIVE_NOT_RECRUITINGConcord, North Carolina, 28025, United States
-
Carolinas Medical Center/Levine Cancer Institute
ACTIVE_NOT_RECRUITINGCharlotte, North Carolina, 28203, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center - Moses Campus
RECRUITINGThe Bronx, New York, 10467, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center-Einstein Campus
RECRUITINGThe Bronx, New York, 10461, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
Contact Phone: •••-•••-••••
-
Rutgers New Jersey Medical School
RECRUITINGNewark, New Jersey, 07101, United States
Contact
Contact Phone: •••-•••-••••
-
University Health Network-Princess Margaret Hospital
SUSPENDEDToronto, Ontario, M5G 2M9, Canada
-
University of Cincinnati Cancer Center-UC Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Cincinnati Cancer Center-West Chester
RECRUITINGWest Chester, Ohio, 45069, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Clinical Research Center
RECRUITINGFairway, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Hospital-Westwood Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kentucky/Markey Cancer Center
ACTIVE_NOT_RECRUITINGLexington, Kentucky, 40536, United States
-
University of Maryland/Greenebaum Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
Contact Phone: •••-•••-••••
-
University of Virginia Cancer Center
SUSPENDEDCharlottesville, Virginia, 22908, United States
-
VCU Massey Comprehensive Cancer Center
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.